CeleCor Therapeutics
Del Mar, US · Founded 2017 · Delaware corporation
CeleCor Therapeutics is developing zalunfiban, an investigational next-generation GPIIb/IIIa platelet inhibitor injected subcutaneously for the pre-hospital treatment of STEMI heart attacks at the first point of medical contact. The company focuses on improving acute myocardial infarction treatment.
BiotechHealthtechMedical Devices
Founders & leadership
PB
Peter B. FinnSecretary
RH
Robert HillmanPresident, Treasurer and Director
RS
Robert S. Hillman, Ph.D.Named on SEC filing
Board
JL
Jack LiefBoard director
AR
Andreas RitziBoard director
Reported raises · per SEC filings
Form D private placements$58.4M disclosed across 3 of 4 rounds · 2017–2026
▶$11.9MraisedJul 2026 · 17 investors · PharmaceuticalsRule 506(b)
▶$11.9MraisedJul 2026 · 17 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert S. Hillman, Ph.D.Executive Officer, Director
- Andreas RitziDirector
- Jack LiefDirector
- Peter B. FinnExecutive Officer
- Offering amount
- $15M
- Amount sold
- $11.9M
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$45.5MraisedAug 2024 · 11 investors · BiotechnologyRule 506(b)
▶$45.5MraisedAug 2024 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jack LiefDirector
- Peter B. FinnExecutive Officer
- Andreas RitziDirector
- Robert HillmanExecutive Officer, Director
- Offering amount
- $45.5M
- Amount sold
- $45.5M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedMay 2021 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedMay 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jack LiefDirector
- Andreas RitziDirector
- Peter B. FinnExecutive Officer
- Robert HillmanExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1M
- Minimum investment
- $250K
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$25MofferedMay 2017 · 5 investors · BiotechnologyRule 506(b)
▶$25MofferedMay 2017 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andreas RitziDirector
- Peter B. FinnExecutive Officer
- Caspar F.V. SturmDirector
- Robert S. HillmanExecutive Officer, Director
- Offering amount
- $25M
- Minimum investment
- $500K
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapCapricor21 shared keywordsCapricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.
Arecor14 shared keywordsArecor develops proprietary therapeutics for diabetes and other cardiometabolic diseases using its Arestat formulation and drug delivery technology platform. It also partners with pharmaceutical and medtech companies to improve therapeutic profiles.
Bioworld13 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Xylocor13 shared keywordsXyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage. The company's lead program, XC001, targets refractory angina in patients with limited treatment options.
Companies competing with CeleCor Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does CeleCor Therapeutics do?
- CeleCor Therapeutics is developing zalunfiban, an investigational next-generation GPIIb/IIIa platelet inhibitor injected subcutaneously for the pre-hospital treatment of STEMI heart attacks at the first point of medical contact. The company focuses on improving acute myocardial infarction treatment.
- How much funding has CeleCor Therapeutics raised?
- CeleCor Therapeutics has disclosed $58.4M raised across 3 of its 4 known rounds.
- Where is CeleCor Therapeutics headquartered?
- CeleCor Therapeutics is headquartered in Del Mar, US.